Anterior Gradient Protein 2 Promotes Mucosal Repair in Pediatric Ulcerative Colitis
Xiaolin Ye1, Jie Wu1, Jing Li2
1Department of Gastroenterology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.
Insights
Anterior gradient protein 2 (AGR2) is elevated in children with ulcerative colitis (UC) and promotes intestinal mucosal repair by activating YAP, suggesting its potential as a biomarker for UC.
Area of Science:
- Gastroenterology
- Molecular Biology
- Pediatric Medicine
Background:
- Mucosal healing is a primary treatment objective in ulcerative colitis (UC).
- Anterior gradient protein 2 (AGR2) is implicated in intestinal homeostasis, but its role in mucosal repair is unclear.
- Investigating AGR2's function in pediatric UC mucosal injury is crucial.
Purpose of the Study:
- To examine AGR2 expression in pediatric UC patients.
- To elucidate AGR2's role in repairing intestinal mucosal injury.
- To explore the molecular mechanisms underlying AGR2's function in UC.
Main Methods:
- Compared AGR2 expression in intestinal tissues of UC patients and healthy controls using immunohistochemistry.
- Evaluated UC disease activity and endoscopic severity.
- Utilized in vitro models to assess AGR2's effect on TNF-α-induced intestinal epithelial barrier injury and YAP activation.
Main Results:
- UC patients exhibited significantly higher intestinal AGR2 expression than controls.
- AGR2 expression positively correlated with Ki67 (cell proliferation) and negatively with endoscopic mucosal injury.
- In vitro, AGR2 overexpression enhanced cell proliferation, migration, and protected against TNF-α-induced barrier damage via YAP activation.
Conclusions:
- AGR2 may serve as a valuable biomarker for assessing UC condition and mucosal healing status.
- AGR2 promotes intestinal mucosal barrier repair by activating YAP.
- Findings highlight AGR2's therapeutic potential in pediatric UC.
Abstract:
Mucosal healing comprises a key goal of ulcerative colitis (UC) treatment. Anterior gradient protein 2 (AGR2) plays an important role in maintaining intestinal homeostasis in UC. However, the role of AGR2 in the repair of mucosal injury is not yet clear. This study is aimed at investigating the expression of AGR2 in the intestinal tissues of children with UC and its role in repairing mucosal injury. Forty UC patients who were hospitalized in the Pediatric Gastroenterology Ward of Shengjing Hospital affiliated with China Medical University between July 1, 2013, and May 31, 2020, and 20 children who had normal colonoscopy results during the same period (control group) made up the study sample. The disease activity of UC was evaluated based on the pediatric ulcerative colitis activity index, and the ulcerative colitis endoscopic index was evaluated according to the Rachmilewitz score. Immunohistochemical staining was employed to examine the differences in AGR2 expression in the intestinal mucosa between groups. The protective effect of AGR2 in a model of tumor necrosis factor-alpha- (TNF-α-) induced intestinal mucosal barrier injury and the underlying molecular mechanism were explored through in vitro experiments. The results showed that compared with the normal control group, UC patients in the remission or active period had significantly higher expression of AGR2 in the intestine. AGR2 expression was positively correlated with Ki67, an intestinal epithelial cell proliferation marker, but negatively correlated with the degree of endoscopic mucosal injury. In an in vitro model, AGR2 overexpression promoted cell proliferation and migration and inhibited TNF-α-induced intestinal epithelial barrier damage by activating yes-associated protein (YAP). Collectively, our study suggests that AGR2 might serve as a valuable biomarker to help assess the condition and mucosal healing status of UC patients. In vitro, AGR2 promoted the repair of intestinal mucosal barrier injury by activating YAP.
More Related Videos
Related Concept Videos
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Renewal of Intestinal Stem Cells
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Mucosal Barrier of the Stomach
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...


